AEON Biopharma, Inc. (NYSE MKT:AEON) — Market Cap & Net Worth
Market Cap & Net Worth: AEON Biopharma, Inc. (AEON)
AEON Biopharma, Inc. (NYSE MKT:AEON) has a market capitalization of $10.48 Million ($10.48 Million) as of May 11, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #26766 globally and #5322 in its home market, demonstrating a -2.49% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AEON Biopharma, Inc.'s stock price $0.90 by its total outstanding shares 11643786 (11.64 Million). Analyse AEON operating cash flow to see how efficiently the company converts income to cash.
AEON Biopharma, Inc. Market Cap History: 2021 to 2026
AEON Biopharma, Inc.'s market capitalization history from 2021 to 2026. Data shows change from $113.06 Million to $10.48 Million (-37.35% CAGR).
AEON Biopharma, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AEON Biopharma, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of AEON by Market Capitalization
Companies near AEON Biopharma, Inc. in the global market cap rankings as of May 11, 2026.
Key companies related to AEON Biopharma, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $109.05 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #360 globally with a market cap of $74.28 Billion USD.
- UCB SA (BR:UCB): Ranked #510 globally with a market cap of $51.74 Billion USD ( €44.26 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #569 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.05 Billion | $429.82 |
| #360 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.28 Billion | $714.89 |
| #510 | UCB SA | BR:UCB | $51.74 Billion | €234.10 |
| #569 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
AEON Biopharma, Inc. Historical Marketcap From 2021 to 2026
Between 2021 and today, AEON Biopharma, Inc.'s market cap moved from $113.06 Million to $ 10.48 Million, with a yearly change of -37.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $10.48 Million | -18.18% |
| 2025 | $12.81 Million | +103.70% |
| 2024 | $6.29 Million | -92.50% |
| 2023 | $83.84 Million | -28.36% |
| 2022 | $117.02 Million | +3.50% |
| 2021 | $113.06 Million | -- |
End of Day Market Cap According to Different Sources
On May 11th, 2026 the market cap of AEON Biopharma, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.48 Million USD |
| MoneyControl | $10.48 Million USD |
| MarketWatch | $10.48 Million USD |
| marketcap.company | $10.48 Million USD |
| Reuters | $10.48 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About AEON Biopharma, Inc.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of ga… Read more